Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Morphic Holding, Inc. (MORF) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 8-K Quarterly results
10/02/2023 SC 13G Point72 Asset Management, L.P. reports a 5.2% stake in Morphic Holding, Inc.
09/26/2023 8-K Quarterly results
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2023 -Reported positive topline results from EMERALD-1study of MORF-057 in ulcerative colitis-"
05/23/2023 144 Form 144 - Report of proposed sale of securities:
05/03/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
05/03/2023 8-K Quarterly results
05/02/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/25/2023 144 Form 144 - Report of proposed sale of securities:
04/25/2023 8-K Quarterly results
04/25/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/25/2023 8-K Quarterly results
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/20/2023 144 Form 144 - Report of proposed sale of securities:
04/17/2023 144 Form 144 - Report of proposed sale of securities:
03/01/2023 D Form D - Notice of Exempt Offering of Securities:
02/23/2023 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
02/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/23/2023 10-K Annual Report for the period ended December 31, 2022
02/23/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022 -Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis&#59; topline data expected 2Q23-"
02/13/2023 8-K Quarterly results
02/09/2023 SC 13G/A FMR LLC reports a 15% stake in MORPHIC HOLDING INC
02/03/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
01/20/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
10/24/2022 8-K Quarterly results
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022 Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis Announced key appointments and advancements in leadership team"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy